Form 4 for PCVX Vaxcyte, Inc.
Accepted 2023-12-05 00:00:00 ET · period of report 2023-12-01 · accession 0001209191-23-057402 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-05 | 2023-12-01 | PCVX | Wassil Jim | COO | S - Sale+OE | $52.14 | -3,000 | 177.9K | -2% | -$156.4K |
| D | 2023-12-05 | 2023-12-01 | PCVX | Wassil Jim | COO | M - OptEx | $2.42 | +3,000 | 178.9K | +2% | +$7,260 |
| D | 2023-12-05 | 2023-12-01 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -3,000 | 96.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-01 | S | D | 1,933 | $52.51 | 175,935 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $52.18 to $52.925. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2023-12-01 | S | D | 1,067 | $51.46 | 177,868 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $51.185 to $52.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2023-12-01 | M | A | 3,000 | $2.42 | 178,935 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2023-12-01 | M | D | 3,000 | $0.00 | 96,555 | D | $2.42 · — to 2029-12-16 | 3,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. |